We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Evolus Inc | NASDAQ:EOLS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.15 | -1.15% | 12.86 | 12.65 | 12.90 | 12.96 | 12.57 | 12.88 | 529,026 | 23:00:06 |
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March.
Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tuesday, March 12th, 2024 Time: 10:00-10:30am ET
Event: The Barclays 26th Annual Global Healthcare Conference Date: Wednesday, March 13th, 2024 Time: 8:00-8:25am ET
The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc. Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227499486/en/
Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications Phone: (248) 202-9267 Email: ir@evolus.com
Media: Email: media@evolus.com
1 Year Evolus Chart |
1 Month Evolus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions